EGFR overexpression has been detected in a significant proportion of head and neck, cervical, non-small cell lung, bladder, pancreatic and colon cancers, as well as in mesothelioma, glioma and other cancers [6], making EGFR a very attractive target for various anti-cancer agents in recent decades. The gene discussed is EGFR; the disease is central nervous system cancer.